Copperleaf Capital LLC Buys 662 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Copperleaf Capital LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 8,704 shares of the medical research company’s stock after acquiring an additional 662 shares during the period. IQVIA accounts for 1.1% of Copperleaf Capital LLC’s portfolio, making the stock its 27th biggest position. Copperleaf Capital LLC’s holdings in IQVIA were worth $1,710,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in IQV. Private Trust Co. NA boosted its holdings in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC boosted its holdings in shares of IQVIA by 1.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after buying an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its holdings in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after buying an additional 50 shares in the last quarter. Fortitude Family Office LLC boosted its holdings in shares of IQVIA by 2.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after buying an additional 56 shares in the last quarter. Finally, Huntington National Bank boosted its holdings in shares of IQVIA by 7.4% during the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after buying an additional 56 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 1.2 %

Shares of NYSE:IQV opened at $193.65 on Friday. The company has a market capitalization of $35.15 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The business has a fifty day moving average price of $200.41 and a two-hundred day moving average price of $218.21. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Truist Financial reaffirmed a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $251.67.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.